FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3095855647> ?p ?o ?g. }

• W3095855647 endingPage "5424" @default.
• W3095855647 startingPage "5414" @default.
• W3095855647 abstract "Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and adults with non-Hodgkin lymphoma (NHL). The initial experience with tisagenlecleucel in a real-world setting from a cellular therapy registry is presented here. As of January 2020, 511 patients were enrolled from 73 centers, and 410 patients had follow-up data reported (ALL, n = 255; NHL, n = 155), with a median follow-up of 13.4 and 11.9 months for ALL and NHL, respectively. Among patients with ALL, the initial complete remission (CR) rate was 85.5%. Twelve-month duration of response (DOR), event-free survival, and overall survival (OS) rates were 60.9%, 52.4%, and 77.2%, respectively. Among adults with NHL, the best overall response rate was 61.8%, including an initial CR rate of 39.5%. Six-month DOR, progression-free survival, and OS rates were 55.3%, 38.7%, and 70.7%, respectively. Grade ≥3 cytokine release syndrome and neurotoxicity were reported in 11.6% and 7.5% of all patients, respectively. Similar outcomes were observed in patients with in-specification and out-of-specification products as a result of viability <80% (range, 61% to 79%). This first report of tisagenlecleucel in the real-world setting demonstrates outcomes with similar efficacy and improved safety compared with those seen in the pivotal trials." @default.
• W3095855647 created "2020-11-09" @default.
• W3095855647 creator A5000537427 @default.
• W3095855647 creator A5001407163 @default.
• W3095855647 creator A5006173110 @default.
• W3095855647 creator A5007397397 @default.
• W3095855647 creator A5012711082 @default.
• W3095855647 creator A5015555817 @default.
• W3095855647 creator A5021394406 @default.
• W3095855647 creator A5029965689 @default.
• W3095855647 creator A5039605313 @default.
• W3095855647 creator A5040185213 @default.
• W3095855647 creator A5042844727 @default.
• W3095855647 creator A5043885981 @default.
• W3095855647 creator A5046048880 @default.
• W3095855647 creator A5048369262 @default.
• W3095855647 creator A5055001531 @default.
• W3095855647 creator A5057939769 @default.
• W3095855647 creator A5064556004 @default.
• W3095855647 creator A5066186106 @default.
• W3095855647 creator A5071401317 @default.
• W3095855647 creator A5071412954 @default.
• W3095855647 creator A5072835425 @default.
• W3095855647 creator A5076832259 @default.
• W3095855647 creator A5077440294 @default.
• W3095855647 creator A5081348202 @default.
• W3095855647 creator A5082333371 @default.
• W3095855647 creator A5086815330 @default.
• W3095855647 creator A5087074127 @default.
• W3095855647 creator A5087189305 @default.
• W3095855647 creator A5087551014 @default.
• W3095855647 creator A5089990813 @default.
• W3095855647 creator A5091433944 @default.
• W3095855647 date "2020-11-04" @default.
• W3095855647 modified "2023-10-17" @default.
• W3095855647 title "Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma" @default.
• W3095855647 cites W1967517831 @default.
• W3095855647 cites W2105400883 @default.
• W3095855647 cites W2567664749 @default.
• W3095855647 cites W2760653955 @default.
• W3095855647 cites W2787301955 @default.
• W3095855647 cites W2793787928 @default.
• W3095855647 cites W2808092337 @default.
• W3095855647 cites W2891902322 @default.
• W3095855647 cites W2903062212 @default.
• W3095855647 cites W2905654445 @default.
• W3095855647 cites W2975143341 @default.
• W3095855647 cites W2990473850 @default.
• W3095855647 cites W2990978976 @default.
• W3095855647 cites W3006233208 @default.
• W3095855647 doi "https://doi.org/10.1182/bloodadvances.2020003092" @default.
• W3095855647 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7656920" @default.
• W3095855647 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33147337" @default.
• W3095855647 hasPublicationYear "2020" @default.
• W3095855647 type Work @default.
• W3095855647 sameAs 3095855647 @default.
• W3095855647 citedByCount "226" @default.
• W3095855647 countsByYear W30958556472020 @default.
• W3095855647 countsByYear W30958556472021 @default.
• W3095855647 countsByYear W30958556472022 @default.
• W3095855647 countsByYear W30958556472023 @default.
• W3095855647 crossrefType "journal-article" @default.
• W3095855647 hasAuthorship W3095855647A5000537427 @default.
• W3095855647 hasAuthorship W3095855647A5001407163 @default.
• W3095855647 hasAuthorship W3095855647A5006173110 @default.
• W3095855647 hasAuthorship W3095855647A5007397397 @default.
• W3095855647 hasAuthorship W3095855647A5012711082 @default.
• W3095855647 hasAuthorship W3095855647A5015555817 @default.
• W3095855647 hasAuthorship W3095855647A5021394406 @default.
• W3095855647 hasAuthorship W3095855647A5029965689 @default.
• W3095855647 hasAuthorship W3095855647A5039605313 @default.
• W3095855647 hasAuthorship W3095855647A5040185213 @default.
• W3095855647 hasAuthorship W3095855647A5042844727 @default.
• W3095855647 hasAuthorship W3095855647A5043885981 @default.
• W3095855647 hasAuthorship W3095855647A5046048880 @default.
• W3095855647 hasAuthorship W3095855647A5048369262 @default.
• W3095855647 hasAuthorship W3095855647A5055001531 @default.
• W3095855647 hasAuthorship W3095855647A5057939769 @default.
• W3095855647 hasAuthorship W3095855647A5064556004 @default.
• W3095855647 hasAuthorship W3095855647A5066186106 @default.
• W3095855647 hasAuthorship W3095855647A5071401317 @default.
• W3095855647 hasAuthorship W3095855647A5071412954 @default.
• W3095855647 hasAuthorship W3095855647A5072835425 @default.
• W3095855647 hasAuthorship W3095855647A5076832259 @default.
• W3095855647 hasAuthorship W3095855647A5077440294 @default.
• W3095855647 hasAuthorship W3095855647A5081348202 @default.
• W3095855647 hasAuthorship W3095855647A5082333371 @default.
• W3095855647 hasAuthorship W3095855647A5086815330 @default.
• W3095855647 hasAuthorship W3095855647A5087074127 @default.
• W3095855647 hasAuthorship W3095855647A5087189305 @default.
• W3095855647 hasAuthorship W3095855647A5087551014 @default.
• W3095855647 hasAuthorship W3095855647A5089990813 @default.
• W3095855647 hasAuthorship W3095855647A5091433944 @default.
• W3095855647 hasBestOaLocation W30958556471 @default.
• W3095855647 hasConcept C121608353 @default.
• W3095855647 hasConcept C126322002 @default.
• W3095855647 hasConcept C143998085 @default.
• W3095855647 hasConcept C187212893 @default.

• next